Joel Greenblatt's LGND Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 9,475 shares of Ligand Pharmaceuticals Incorporated (LGND) worth $1.68 M, representing 0.01% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in LGND, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2014, adding 496,561 shares. Largest reduction occurred in Q4 2014, reducing 548,287 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Ligand Pharmaceuticals Incorporated (LGND) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ligand Pharmaceuticals Incorporated (LGND) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2013 | +6,136 | New Buy | 6,136 | $43.35 |
| Q4 2013 | +7,667 | Add 124.95% | 13,803 | $52.60 |
| Q1 2014 | -13,803 | Sold Out | 13,803 | $0.00 |
| Q2 2014 | +55,492 | New Buy | 55,492 | $62.30 |
| Q3 2014 | +496,561 | Add 894.83% | 552,053 | $46.99 |
| Q4 2014 | -548,287 | Reduce 99.32% | 3,766 | $53.11 |
| Q1 2015 | -3,766 | Sold Out | 3,766 | $0.00 |
| Q1 2016 | +21,822 | New Buy | 21,822 | $107.09 |
| Q2 2016 | +50,048 | Add 229.35% | 71,870 | $119.27 |
| Q3 2016 | -33,639 | Reduce 46.81% | 38,231 | $102.06 |
| Q4 2016 | -4,266 | Reduce 11.16% | 33,965 | $101.60 |
| Q1 2017 | +83,784 | Add 246.68% | 117,749 | $105.84 |
| Q2 2017 | -117,749 | Sold Out | 117,749 | $0.00 |
| Q4 2017 | +52,100 | New Buy | 52,100 | $136.93 |
| Q1 2018 | -35,790 | Reduce 68.69% | 16,310 | $165.17 |
| Q2 2018 | -2,319 | Reduce 14.22% | 13,991 | $207.20 |
| Q3 2018 | +13,820 | Add 98.78% | 27,811 | $274.50 |
| Q4 2018 | -11,254 | Reduce 40.47% | 16,557 | $135.71 |
| Q1 2019 | +8,878 | Add 53.62% | 25,435 | $125.69 |
| Q2 2019 | +39,236 | Add 154.26% | 64,671 | $114.15 |
| Q3 2019 | -62,546 | Reduce 96.71% | 2,125 | $99.76 |
| Q4 2019 | +343 | Add 16.14% | 2,468 | $104.13 |
| Q1 2020 | -2,468 | Sold Out | 2,468 | $0.00 |
| Q4 2020 | +3,715 | New Buy | 3,715 | $99.33 |
| Q1 2021 | -1,679 | Reduce 45.20% | 2,036 | $152.26 |
| Q2 2021 | +526 | Add 25.83% | 2,562 | $131.15 |
| Q3 2021 | -155 | Reduce 6.05% | 2,407 | $139.18 |
| Q4 2021 | +1,051 | Add 43.66% | 3,458 | $154.42 |
| Q1 2022 | +1,122 | Add 32.45% | 4,580 | $112.45 |
| Q2 2022 | -1,437 | Reduce 31.38% | 3,143 | $89.09 |
| Q3 2022 | +1,400 | Add 44.54% | 4,543 | $86.07 |
| Q4 2022 | -4,543 | Sold Out | 4,543 | $0.00 |
| Q1 2023 | +4,245 | New Buy | 4,245 | $73.56 |
| Q2 2023 | +5,037 | Add 118.66% | 9,282 | $72.10 |
| Q3 2023 | -1,799 | Reduce 19.38% | 7,483 | $59.92 |
| Q4 2023 | -3,300 | Reduce 44.10% | 4,183 | $71.42 |
| Q1 2024 | -4,183 | Sold Out | 4,183 | $0.00 |
| Q1 2025 | +6,912 | New Buy | 6,912 | $105.14 |
| Q2 2025 | -6,912 | Sold Out | 6,912 | $0.00 |
| Q3 2025 | +9,475 | New Buy | 9,475 | $177.14 |
Joel Greenblatt's Ligand Pharmaceuticals Incorporated Investment FAQs
Joel Greenblatt first purchased Ligand Pharmaceuticals Incorporated (LGND) in Q3 2013, acquiring 6,136 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Ligand Pharmaceuticals Incorporated (LGND) for 49 quarters since Q3 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to Ligand Pharmaceuticals Incorporated (LGND) was in Q3 2014, adding 552,053 shares worth $25.94 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 9,475 shares of Ligand Pharmaceuticals Incorporated (LGND), valued at approximately $1.68 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Ligand Pharmaceuticals Incorporated (LGND) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in Ligand Pharmaceuticals Incorporated (LGND) was 552,053 shares, as reported at the end of Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.